Tests long-term safety of HRS-1893 tablets in hypertrophic cardiomyopathy
Studies the long-term safety of HRS-1893 tablets in adults with hypertrophic cardiomyopathy.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07021963, who can take part
Where in China
- Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shandong Suncadia Medicine Co., Ltd.
- Trial code
- NCT07021963
- Record updated
- 10 September 2025
- Original description
This study mainly evaluates the long-term safety of HRS-1893 in subjects with hypertrophic cardiomyopathy.Read full original descriptionShow less
A Multicenter, Open-label Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
This study mainly evaluates the long-term safety of HRS-1893 in subjects with hypertrophic cardiomyopathy.
Inclusion: Subjects with hypertrophic cardiomyopathy who have previously completed HRS-1893 related studies; Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating during the study. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time they sign the informed consent form until 3 months after the last dose of trial drug, and to comply with relevant contraceptive requirements; Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.
Exclusion: Previous history of coronary artery disease (stenosis of one or more coronary arteries >70%) or myocardial infarction; Have received medication for negative inotropic other than disopyramide, β-blocker, verapamil, diltiazem 4 weeks before screening; History of syncope or sustained ventricular tachycardia within 6 months prior to screening; Other conditions that the investigator considers the subject to be unsuitable for participating in this trial, such as physical or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial.